InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) mmRNA Device Now Covered by, Billable to Medicare
December 14, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced that it has received acceptance from a Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding (“PDAC”) contractor for its mmRNA (modified […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Officially Registers with Health Canada
December 9, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has registered with Health Canada, a key step in being able to manufacture and sell its proprietary sleep disorder, snoring and sleep apnea appliances […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference
December 3, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. The event […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q3 2021 Financial, Operational Report
November 16, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has released is third-quarter 2021 financial report; the company also reported on operational highlights. The report noted that VVOS Q3 revenue increase […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Q4 Virtual Investor Summit
November 15, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”), will be presenting at the upcoming Q4 Virtual Investor Summit. The summit is scheduled for Nov. 17, 2021. Vivos CEO Kirk Huntsman, chief financial officer Brad Amman, and investor relations officer […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Scheduled Release of Q3 2021 Financial Results, Conference Call
November 9, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it plans to release financial results for the third quarter ended Sept. 30, 2021, after market close on Monday, […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference
October 22, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Showcasing Innovations in OSA Treatment at 2021 Annual Breathing Wellness Conference
October 20, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute. The event is taking place at Caesars Palace in Las Vegas, Nevada, […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid to Bring Airway and Sleep, Oral Health, Orthodontic Therapy Together in Comprehensive Solution
October 19, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, have announced a new collaboration. Under the partnership, the companies will seek to provide patients with a […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution
October 18, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution […]
InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study
October 13, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology
September 23, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference
September 22, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment
August 26, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance for mmRNA Oral Appliance
August 23, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study
August 18, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report
August 13, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Q3 Virtual Investor Summit
August 10, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), will participate in the upcoming two-day Q3 Virtual Investor Summit. Vivos CEO Kirk Huntsman along with CFO Brad Amman and Ed Loew, Vivos investor relations […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Discuss Q2 2021 Financial Results
August 9, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has scheduled a conference call and live webcast for Aug. 12, 2021, to begin at 5 p.m. ET. The purpose of the call is to […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center
July 29, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology
July 13, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome
July 7, 2021
Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the […]
InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book
July 1, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. […]
Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book
June 25, 2021
Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation The book mainly covers craniofacial growth and developmental Genetics It also highlights the relationship […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Unique System That Rebuilds Human Airway on Relentless Dentist Podcast
June 9, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), was featured in a recent episode of the Relentless Dentist podcast. The program features interviews with thought-provoking guests offering words of wisdom to help dentists gain the courage […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder, CEO Authors Book Focused on Groundbreaking Work
May 26, 2021
Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Appoints Widely Acclaimed Leader as New Medical Director of Clinical Education
April 14, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Upcoming Emerging Growth Conference
April 12, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), will be presenting at the Emerging Growth Conference this week. VVOS CEO Kirk Huntsman, along with chief financial officer Brad Amman and investor relations officer Ed Loew, will host […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils New MyoCorrect Orofacial Myofunctional Therapy Service
March 30, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2020 Financial, Operational Results
March 26, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Biotech Conference
March 23, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, […]
Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Virtual Coverage of Investor Summit Group’s Q1 Virtual Summit
March 22, 2021
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Release, Discuss Q4, FY 2020 Financial Results
March 18, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), plans to release its fourth-quarter and full-year financial reports on March 25, 2021, after market close; the numbers will cover the period ending Dec. 31, 2020. The company has […]
Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
March 16, 2021
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Leaders to Present at Upcoming Virtual Investor Summit
March 11, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”) has announced that CEO Kirk Huntsman, CFO Brad Amman and investor relations officer Ed Loew are scheduled to present at the Q1 Virtual Investor Summit. Vivos Therapeutics’ presentation is […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA 510(k) Application for Exclusive Oral Appliance
March 10, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), recently submitted an application to the U.S. Food and Drug Administration (“FDA”) for its mmRNA (“mmRNA”) oral appliance(TM). The 510(k) Class II application focuses on the oral appliance as […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens First-Ever Pneusomnia Clinic, Unveils New Tech to Test for Sleep Apnea at Home
March 8, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has opened the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center. The center will feature the Vivos System through its Medical Integration Division. Located in Del Mar, California, the clinic is […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Establishes Clinical Advisory Board to Help Drive Growth
March 5, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), announced the creation of its new Clinical Advisory Board. The six-member board will focus on driving adoption and growth of Vivos’ next-gen treatments for OSA. Reports indicate that an […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Secures $24.2M in Initial Public Offering
February 10, 2021
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, has closed its initial public offering of 4,025,000 shares of its common stock, including an additional 525,000 shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Vivos […]